Inhibition by Aplidine of the aggregation of the prion peptide PrP 106-126 into β-sheet fibrils

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1639, Issue 2, 2003, Pages 133-139

  Pérez, Mar ^a   Sadqi, Mourad ^b   Muñoz, Victor ^b   Ávila, Jesús ^a  

^a CSIC   (Spain)

^b Bldg 142   (United States)

Author keywords

Aplidine; Inhibition of aggregation; Prion peptide

Indexed keywords

CYCLOPEPTIDE; DEHYDRODIDEMNIN B; PRION PROTEIN; DEPSIPEPTIDE; PEPTIDE FRAGMENT; PRION PROTEIN (106 126); PRION PROTEIN (106-126);

AMINO ACID SEQUENCE; ARTICLE; BETA SHEET; CELL MEMBRANE; FIBER; PRIORITY JOURNAL; ANIMAL; ELECTRON MICROSCOPY; METABOLISM; PRION; PROTEIN QUATERNARY STRUCTURE; ULTRASTRUCTURE; UROCHORDATA;

APLIDIUM;

ANIMALS; DEPSIPEPTIDES; MICROSCOPY, ELECTRON; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC; PRIONS; PROTEIN STRUCTURE, QUATERNARY; UROCHORDATA;

EID: 0642345073     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2003.08.003     Document Type: Article

References (24)

1. Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Annu. Rev. Neurosci. 24:2001;519-550.
2. Hope J. Prions and neurodegenerative diseases. Curr. Opin. Genet. Dev. 10:2000;568-574.
3. Prusiner S.B. Prions. Proc. Natl. Acad. Sci. U. S. A. 95:1998;13363-13383.
4. Wong C., Xiong L.W., Horiuchi M., Raymond L., Wehrly K., Chesebro B., Caughey B. Sulfated glycans and elevated temperature stimulate PrP(Sc) -dependent cell-free formation of protease-resistant prion protein. EMBO J. 20:2001;377-386.
5. Bolton D.C., McKinley M.P., Prusiner S.B. Identification of a protein that purifies with the scrapie prion. Science. 218:1982;1309-1311.
6. Prusiner S.B. Prion diseases and the BSE crisis. Science. 278:1997;245-251.
7. Haywood A.M. Transmissible spongiform encephalopathies. N. Engl. J. Med. 337:1997;1821-1828.
8. Johnson R.T., Gibbs C.J. Jr. Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. N. Engl. J. Med. 339:1998;1994-2004.
9. Alper T., Cramp W.A., Haig D.A., Clarke M.C. Does the agent of scrapie replicate without nucleic acid? Nature. 214:1967;764-766.
10. Bueler H., Aguzzi A., Sailer A., Greiner R.A., Autenried P., Aguet M., Weissmann C. Mice devoid of PrP are resistant to scrapie. Cell. 73:1993;1339-1347.
11. Tagliavini F., Lievens P.M., Tranchant C., Warter J.M., Mohr M., Giaccone G., Perini F., Rossi G., Salmona M., Piccardo P., Ghetti B., Beavis R.C., Bugiani O., Frangione B., Prelli F. A 7-kDa prion protein (PrP) fragment, an integral component of the PrP region required for infectivity, is the major amyloid protein in Gerstmann-Straussler-Scheinker disease A117V. J. Biol. Chem. 276:2001;6009-6015.
12. Kaneko K., Ball H.L., Wille H., Zhang H., Groth D., Torchia M., Tremblay P., Safar J., Prusiner B., DeArmond S.J., Baldwin M.A., Cohen F.E. A synthetic peptide initiates Gerstmann-Straussler-Scheinker (GSS) disease in transgenic mice. J. Mol. Biol. 295:2000;997-1007.
13. Liemann S., Glockshuber R. Transmissible spongiform encephalopathies. Biochem. Biophys. Res. Commun. 250:1998;187-193.
14. Forloni G., Angeretti N., Chiesa R., Monzani E., Salmona M., Bugiani O., Tagliavini F. Neurotoxicity of a prion protein fragment. Nature. 362:1993;543-546.
15. Perez M., Wandosell F., Colaco C., Avila J. Sulphated glycosaminoglycans prevent the neurotoxicity of a human prion protein fragment. Biochem. J. 335(Pt. 2):1998;369-374.
16. De Gioia L., Selvaggini C., Ghibaudi E., Diomede L., Bugiani O., Forloni G., Tagliavini F., Salmona M. Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. J. Biol. Chem. 269:1994;7859-7862.
17. Chabry J., Caughey B., Chesebro B. Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. J. Biol. Chem. 273:1998;13203-13207.
18. Soto C., Kascsak R.J., Saborio G.P., Aucouturier P., Wisniewski T., Prelli F., Kascsak R., Mendez E., Harris A., Ironside J., Tagliavini F., Carp R.I., Frangione B. Reversion of prion protein conformational changes by synthetic b sheet breaker peptides. Lancet. 355:2000;192-197.
19. Geldof A.A., Mastbergen S.C., Henrar R.E., Faircloth G.T. Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays. Cancer Chemother. Pharmacol. 44:1999;312-318.
20. Forloni G., Tagliavini F., Bugiani O., Salmona M. Amyloid in Alzheimer's disease and prion-related encephalopathies: studies with synthetic peptides. Prog. Neurobiol. 49:1996;287-315.
21. Woods A.G., Cribbs D.H., Whittemore E.R., Cotman C.W. Heparan sulfate and chondroitin sulfate glycosaminoglycan attenuate beta-amyloid(25-35) induced neurodegeneration in cultured hippocampal neurons. Brain Res. 697:1995;53-62.
22. Crowther R.A., Olesen O.F., Smith M.J., Jakes R., Goedert M. Assembly of Alzheimer-like filaments from full-length tau protein. FEBS Lett. 337:1994;135-138.
23. Sadqi M., Hernandez F., Pan U., Perez M., Schaeberle M.D., Avila J., Munoz V. Alpha-helix structure in Alzheimer's disease aggregates of tau-protein. Biochemistry. 41:2002;7150-7155.
24. Modler A.J., Gast K., Lutsch G., Damaschun G. Assembly of amyloid protofibrils via critical oligomers - a novel pathway of amyloid formation. J. Mol. Biol. 325:2003;135-148.